（原标题：港股异动 | 周大福创建(00659)再涨超4% 战略投资带动利润超预期 机构称派息符合预期） 消息面上，周大福创建近期发布截至6月底全年业绩，公司股东应占溢利上升4%至21.62亿港元。里昂 发布研报称，周大福创建下半财年经常性利润同比增长18%至14亿元，由于公司的战略投资带动更高贡 献，其表现较预期高出19%。末期息派0.35港元，同比持平，基本符合预期，公司亦建议进行十送一红 股。 此外，周大福创建宣布拟发行于2028年到期的22.18亿港元0.75%可交换债券，交换财产为其持有的首程 控股约10.0%的已发行股本。交易完成后，周大福创建将退出对首程控股的投资。中金表示，将此次交 易视为首程控股进一步优化其持股结构的重要契机；此次交易完成后，首程控股流动性将显著改善。 智通财经APP获悉，周大福创建(00659)再涨超4%，截至发稿，涨3.82%，报8.42港元，成交额4606.77万 港元。 ...

银河证券表示，掘金"十五五"，聚焦军贸&新质领域。装备采购方面，"十五五"预期积极，订单端牵引 有望于25Q4启动。同时聚焦27年建军百年重要节点，新型主战装备批产交付与新质战斗力领域需求爆 发，拉动行业高景气延续。 （原标题：港股异动 | 中船防务(00317)涨超5% 机构指其受益全球造船周期上行与自身产能释放） 智通财经APP获悉，中船防务(00317)涨超5% ，截至发稿，涨5.63%，报15.58港元，成交额8591.43万港 元。 消息面上，申万宏源近期指出，首予中船防务"买入"评级。公司受益于全球造船周期上行与自身产能释 放，预计2025-2027年归母净利润分别为11、17、28亿元，对应PE分别为18、11、7倍，当前市值/手持 订单金额(PO)为0.42倍，显著低于近10年均值(0.53倍)，处于历史低位。结合高价订单交付提速、老船 替换需求充足及同业竞争解决预期，公司业绩弹性与估值修复空间充足。 ...

来凯医药-B(02105)早盘涨超7%，截至发稿，涨8.42%，报13.9港元，成交额3424.37万港元。 财通证券（601108）此前指出，ActRII通路作为肌肉调控的关键通路，吸引多家跨国药企布局，公司围 绕ActRII通路布局三款增肌产品：LAE102目前已完成SAD研究，安全性较好，目前正在开展MAD研 究；2024年11月公司与礼来签订LAE102的临床合作协议，由礼来负责在美国开展1期临床并承担相关费 用，公司保留LAE102的全球权益，体现出礼来对LAE102产品看好，已启动美国1期临床。此外，公司 计划分别于2Q2025/3Q2025提交LAE103/LAE123临床试验申请。 消息面上，来凯医药宣布，完成发行3600万股配售股份，每股配售股份16.30港元，所得款项净额约5.77 亿港元。拟将用于ActRII产品组合的研发开支；临床前候选药物的持续研发开支；一般及企业用途。董 事会预计，额外资金对于推进集团ActRII产品组合的持续研发活动以及支持持续进行的临床前研发活动 而言至关重要。 ...

创新药板块普涨之后，择时、择股重要性明显提升，该行继续建议在板块回调时逐步布局，并建议关注 以下细分方向：1)创新药：三生制药(01530)、德琪医药-B(06996)短期催化剂丰富、估值仍未反映核心 大单品价值，先声药业(02096)、和黄医药(00013)、传奇生物被明显低估、长期成长逻辑清晰;2)CXO： 受益于下游高景气度和融资边际回暖的细分赛道龙头，如药明合联(02268)。 创新药保障模式逐步成形，未来落地可望缓解企业的进院难、报销支付难等情况。ESMO大会将于10月 中下旬举行，该行建议重点关注康方生物(09926)、科伦博泰生物-B(06990)、荣昌生物(09995)等有重磅 数据读出的公司。 交银国际发布研报称，本周恒生医疗保健指数跌1.4%，跑输大市。其中，互联网医药、CXO及中药板 块表现较优于其他板块。该行表示,9月以来，内资透过港股通的持股比例保持稳定，而外资的持仓则从 年中开始略为回落，但内外资持续加大创新药企布局的大方向不变。本周，内资关注补涨机会，外资亦 加仓长期潜力大、当前性价比较高的创新药标的，及潜在受益于降息周期的CXO企业。 ...

银河证券表示，掘金"十五五"，聚焦军贸&新质领域。装备采购方面，"十五五"预期积极，订单端牵引 有望于25Q4启动。同时聚焦27年建军百年重要节点，新型主战装备批产交付与新质战斗力领域需求爆 发，拉动行业高景气延续。 消息面上，申万宏源近期指出，首予中船防务"买入"评级。公司受益于全球造船周期上行与自身产能释 放，预计2025-2027年归母净利润分别为11、17、28亿元，对应PE分别为18、11、7倍，当前市值/手持 订单金额(PO)为0.42倍，显著低于近10年均值(0.53倍)，处于历史低位。结合高价订单交付提速、老船 替换需求充足及同业竞争解决预期，公司业绩弹性与估值修复空间充足。 中船防务（600685）(00317)涨超5%，截至发稿，涨5.63%，报15.58港元，成交额8591.43万港元。 ...

Group 1 - The core viewpoint of the articles highlights the significant rise of Ark Health (方舟健客) stock, which increased by 8.23% to HKD 4.34, with a trading volume of HKD 40.77 million, following a report in Nature about China's medical AI models [1] - The Nature report emphasizes China's chronic disease management model, which integrates AI with various chronic disease management practices, showcasing a successful case that is rare globally [1] - The report indicates that while there are few large-scale companies in the overseas market that deeply integrate AI with chronic disease management, China's innovative forces are emerging in this field, potentially allowing for a leapfrog development [1] Group 2 - Ark Health's "super digital brain," the Xing Shi model, drives five major applications: AI medication assistant, AI health manager, AI doctor assistant, AI academic assistant, and AI search, each tailored for specific clinical and patient scenarios [2] - Each application provides real-time and precise assistance in areas such as medication guidance, patient education, diagnostic support, and medical literature queries [2] - The AI academic assistant product enhances efficiency and user engagement by offering expert-level answers with voice interaction capabilities, catering to the busy clinical environment of doctors [2]

Group 1 - China Everbright Holdings (00165) experienced a cumulative increase of 37% over the past two trading days, but saw a decline of over 15% this morning, currently down 13.68% at HKD 11.04 with a trading volume of HKD 739 million [1] - Everbright Holdings is a leader in China's private equity investment, with two main business segments: private asset management and proprietary capital investment [1] - The company invested 11.98% in Shanghai Micro Electronics Equipment Co., Ltd. through its subsidiary Everbright Qingdao in April 2016 [1] Group 2 - Recent rumors regarding Shanghai Micro Electronics' potential "backdoor listing" have resurfaced, as the company has faced obstacles in its IPO process since it entered the listing guidance in December 2017 and withdrew its IPO filing in October last year [1] - Industry investment insiders speculate that Shanghai Micro Electronics may opt for a backdoor listing to avoid significant flaws in the IPO process [1]

Core Viewpoint - Hebei Haiwei Electronic New Materials Technology Co., Ltd. has refiled its application for listing on the Hong Kong Stock Exchange after its initial application expired, indicating its ongoing ambition to expand in the capacitor film manufacturing industry [1][2]. Company Overview - Haiwei Electronic is a manufacturer of capacitor films, producing key components such as capacitor base films and metallized films, which are widely used in various sectors including new energy vehicles and industrial equipment [1][3]. - The company has been recognized as the second-largest capacitor film manufacturer in China based on projected sales for 2024 [1][4]. Financial Performance - Revenue from 2022 to 2024 shows a steady increase from 327 million RMB to 422 million RMB, while net profit has fluctuated, decreasing from 102 million RMB in 2022 to 86.4 million RMB in 2024 [1][5]. - In the first five months of 2025, revenue declined by approximately 3.2% to 157 million RMB, and net profit decreased by about 4.56% to 31.4 million RMB [1][6]. Market Dynamics - The capacitor film market in China is projected to grow significantly, with the market size increasing from 1.2 billion RMB in 2019 to 3.6 billion RMB in 2024, reflecting a compound annual growth rate (CAGR) of 24.2% [8][11]. - Haiwei Electronic holds a market share of 14.2% in the capacitor base film market, ranking second among the top five players, which collectively hold 61.6% of the market [11][12]. Production Capacity and Expansion Plans - The company plans to double its production capacity by adding four new capacitor base film production lines by 2027, which will significantly enhance its market presence [12][13]. - Haiwei Electronic's production capacity utilization has been high, reaching 98.8% in 2024, indicating strong demand for its products [13][14]. New Business Ventures - The company is expanding into the composite copper foil market, which is expected to grow from 11.09 billion RMB in 2025 to 49.47 billion RMB by 2029, with a CAGR of 45.3% [15]. - This new venture is anticipated to become a significant growth driver for Haiwei Electronic, potentially enhancing its valuation [15].

此外，周大福创建宣布拟发行于2028年到期的22.18亿港元0.75%可交换债券，交换财产为其持有的首程 控股约10.0%的已发行股本。交易完成后，周大福创建将退出对首程控股的投资。中金表示，将此次交 易视为首程控股进一步优化其持股结构的重要契机；此次交易完成后，首程控股流动性将显著改善。 周大福创建(00659)再涨超4%，截至发稿，涨3.82%，报8.42港元，成交额4606.77万港元。 消息面上，周大福创建近期发布截至6月底全年业绩，公司股东应占溢利上升4%至21.62亿港元。里昂 发布研报称，周大福创建下半财年经常性利润同比增长18%至14亿元，由于公司的战略投资带动更高贡 献，其表现较预期高出19%。末期息派0.35港元，同比持平，基本符合预期，公司亦建议进行十送一红 股。 ...

Group 1 - Wind power stocks in Hong Kong rose against the market trend, with increases of over 7%, 5%, and nearly 5% among various companies [1] - Morgan Stanley upgraded the rating of the Chinese wind power industry, suggesting that the sector may experience a recovery following efforts to combat internal competition [2] - The report indicates that after a challenging period from 2022 to 2024, the Chinese wind power industry successfully reversed the trend of vicious competition through self-regulation [3] Group 2 - Morgan Stanley forecasts that during the "14th Five-Year Plan" period, the average annual new installed capacity will exceed 110 GW, potentially reaching around 120 GW between 2028 and 2030 [3] - The investment opportunities are particularly favorable for key component suppliers and submarine cable companies within the wind power value chain [2]